Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue EstimatesPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by David Maisel: https://img.theapi.app/temp/0e9d087d-988e-4397-b7cf-6049e2776769.png
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

Urogen Pharma (URGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $1.05 per share a year ago. These figures

Zacks 
0 05.08.26
Urogen Pharma Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by David Maisel: https://img.theapi.app/temp/0e9d087d-988e-4397-b7cf-6049e2776769.png
Urogen Pharma Q2 Earnings Call Highlights

Key Points

MarketBeat 
0 05.08.26
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great ChoicePhoto, wide shot, wide-angle lens, Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even

Zacks 
0 14.08.26